TRCT
IHE icon

Tower Research Capital (TRC)’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Tower Research Capital (TRC)’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Buy
+22,455
New +$2.02M 0.05% 311
2025
Q4 		– Sell
-8,159
Closed -$592K – 5356
2025
Q3 		$592K Sell
8,159
-9,957
-55% -$687K 0.02% 756
2025
Q2 		$1.19M Buy
18,116
+3,728
+26% +$243K 0.03% 475
2025
Q1 		$1.02M Buy
+14,388
New +$1,000K 0.03% 492
2024
Q4 		– Sell
-4,012
Closed -$283K – 5829
2024
Q3 		$283K Buy
4,012
+3,207
+398% +$223K 0.01% 1304
2024
Q2 		$53.4K Sell
805
-5,613
-87% -$368K ﹤0.01% 3055
2024
Q1 		$436K Sell
6,418
-123,653
-95% -$8.17M 0.01% 942
2023
Q4 		$8.04M Buy
130,071
+124,440
+2,210% +$7.31M 0.1% 161
2023
Q3 		$332K Sell
5,631
-180
-3% -$11K 0.01% 1119
2023
Q2 		$347K Sell
5,811
-354
-6% -$21K 0.01% 1214
2023
Q1 		$360K Buy
6,165
+4,401
+249% +$265K 0.01% 1026
2022
Q4 		$109K Sell
1,764
-10,725
-86% -$645K ﹤0.01% 1766
2022
Q3 		$706K Sell
12,489
-35,805
-74% -$2.21M 0.01% 889
2022
Q2 		$3.08M Buy
48,294
+42,600
+748% +$2.7M 0.07% 234
2022
Q1 		$369K Buy
+5,694
New +$361K ﹤0.01% 1333
2021
Q4 		– Sell
-2,055
Closed -$125K – 6335
2021
Q3 		$125K Buy
+2,055
New +$131K ﹤0.01% 2206
2021
Q2 		– Sell
-7,191
Closed -$426K – 5639
2021
Q1 		$426K Sell
7,191
-104,745
-94% -$6.32M 0.01% 1372
2020
Q4 		$6.7M Buy
111,936
+104,082
+1,325% +$5.93M 0.2% 46
2020
Q3 		$428K Sell
7,854
-17,667
-69% -$953K ﹤0.01% 1855
2020
Q2 		$1.31M Buy
+25,521
New +$1.28M 0.05% 375
2019
Q4 		– Sell
-1,134
Closed -$53K – 3903
2019
Q3 		$53K Sell
1,134
-21,072
-95% -$1.01M ﹤0.01% 1759
2019
Q2 		$1.12M Sell
22,206
-7,698
-26% -$381K 0.08% 236
2019
Q1 		$1.53M Buy
+29,904
New +$1.49M 0.09% 169
2018
Q4 		– Sell
-8,904
Closed -$498K – 4056
2018
Q3 		$498K Sell
8,904
-1,431
-14% -$78.2K 0.04% 477
2018
Q2 		$521K Buy
+10,335
New +$512K 0.03% 627
2016
Q1 		– Sell
-91,428
Closed -$4.93M – 4497
2015
Q4 		$4.93M Sell
91,428
-6,645
-7% -$350K 0.8% 12
2015
Q3 		$4.84M Buy
98,073
+72,609
+285% +$4.16M 0.47% 22
2015
Q2 		$1.48M Buy
25,464
+10,545
+71% +$616K 0.13% 69
2015
Q1 		$857K Sell
14,919
-6,906
-32% -$378K 0.11% 121
2014
Q4 		$1.1M Sell
21,825
-53,325
-71% -$2.6M 0.11% 90
2014
Q3 		$3.52M Buy
75,150
+49,737
+196% +$2.24M 0.39% 44
2014
Q2 		$1.14M Sell
25,413
-87,489
-77% -$3.76M 0.15% 78
2014
Q1 		$4.77M Buy
112,902
+100,050
+778% +$4.19M 0.61% 26
2013
Q4 		$506K Buy
+12,852
New +$482K 0.08% 180

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Tower Research Capital (TRC)'s IHE Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 22,455 shares worth $2.22M. The stake represents 0.05% of the portfolio and ranks #311 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in IHE as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in IHE in Q4 2013 and has held it in 34 quarters since. The position peaked at $8.04M in Q4 2023. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Tower Research Capital (TRC) held 22,455 shares of iShares US Pharmaceuticals ETF worth $2.22M as of Q2 2026.
  • iShares US Pharmaceuticals ETF was a new Tower Research Capital (TRC) position in Q2 2026.
  • iShares US Pharmaceuticals ETF made up 0.05% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #311 holding.
  • Tower Research Capital (TRC) first reported a position in iShares US Pharmaceuticals ETF in Q4 2013 and has held it in 34 quarters since.
  • Tower Research Capital (TRC)'s iShares US Pharmaceuticals ETF position peaked at $8.04M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.